Crispina Calsada - 10 May 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Financial Officer
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
10 May 2022
Net transactions value
$0
Form type
4
Filing time
11 May 2022, 16:34:36 UTC
Previous filing
26 Jan 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 10 May 2022 Common Stock 50,000 $1.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests only upon achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone and verification of same by the Company's Compensation Committee, one hundred percent of the shares immediately vested.